

Board of Governors Meeting

via Teleconference/Webinar

September 15, 2020
1:00 PM – 4:45 PM

Welcome and Introductions

Christine Goertz, DC, PhD

Chairperson, Board of Governors

Agenda



1:00 PM	Call to Order and Welcome
1:00-1:45	PCORnet Update • Consider for Approval: PCORnet Extension Funding
1:45-2:30	Consider for Approval: • Commitment Plan Model • FY2021 Expense Budget
2:45-3:15	Strategic Planning Committee Report to the Board
3:15-4:15	Panel Discussion with Outgoing Board Members
4:15-4:45	Public Comment
4:45	Wrap-up and Adjournment

PCORnet Update

Infrastructure Funding to Advance PCORnet

Josephine P. Briggs, MD

Senior Advisor to the Executive Director



Request to Commit FY2020 Budgeted Funds to Extend PCORnet Infrastructure Projects




- September 18, 2019, the Board approved PCORI's proposed budget for the 2020 fiscal year including \$37 million for PCORnet funding
- We are requesting approval to **commit \$17 million in FY2020 budgeted funds** to extend the PCORnet networks and Coordinating Center infrastructure projects
- **No new unbudgeted funds** are requested for the extension
- Internal and external PCORnet evaluation will be completed by December 2020 which will inform Board commitments on next steps
- The extension funding will maintain the PCORnet networks and the Coordinating Center while PCORI critically assesses network capabilities and to allow adequate time for Strategic Committee and Board Consideration for development of Phase 3 PFA solicitations and external merit review process


309 Publications about PCORnet

- Publications and presentations about PCORnet infrastructure and research have increased over time

Marquis-Gravel G, Roe M, Robertson H et al. Rationale and Design of the Aspirin Dosing – A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial. *JAMA Cardiol.* 2020; 5(5): 598-607.














Arterburn D, Wellman R, Emiliano A et al. Comparative effectiveness and safety of bariatric procedures for weight loss. *Ann Intern Med.* 2018; 169(11): 741-750.



Highest scored publication to date from 2018


Includes data from PCORI as of Q3 August 1, 2020. N=309



PCORnet Front Door

Total Visitors November 1, 2018 – August 3, 2020 = 262


- The PCORnet Front Door team interacts with a variety of requestors that are interested in leveraging PCORnet resources.
- An intake team educates requestors, advises on research designs, and connects opportunities with investigators across the Network



Includes data from November 1, 2018 to August 3, 2020. Requests are attributed to the month they are received. **Requests include:** Data Network Requests as well as the status of Active and Closed Requests based on requestor self-report and Front Door assessment. Network Collaborator Requests and Study Designation Requests were discontinued prior to November 1, 2018 with the initiation of PCORnet 2.0.

Who Visits the Front Door?


- Requestors are frequently academic investigators, but also include funders representing federal, foundation, and industry partners



Includes data based on requestor self-report and Front Door assessment from November 1, 2018 to August 3, 2020. Requests are attributed to the year they are received.

Why do they Visit the Front Door?


- Requestors often require consultation and support to understand how to leverage PCORnet resources to enhance their research
- In some instances, the Front Door team supports proposal development, including how to properly budget for a project utilizing PCORnet partners and resources



Includes data based on requestor self-report and Front Door assessment from November 1, 2018 to August 3, 2020. Network Collaborator Requests and Study Designation Requests were discontinued prior to November 1, 2018 with the initiation of PCORnet 2.0.

What Funders do Front Door Visitors Target?

- Front Door visitors seeking to use PCORnet for research funded by variety of sources
- Targeted funders include the NIH, foundations, industry, and PCORI



Targeted-intention or plan to submit to an identified funding source; Not applicable: information seeking only and/or not a good fit for PCORnet resources. Includes data based on requestor self-report and Front Door assessment from November 1, 2018 to August 3, 2020. Network Collaborator Requests and Study Designation Requests were discontinued prior to November 1, 2018 with the initiation of PCORnet 2.0.

PCORnet Use in Current PCORI Funding Opportunities



- **Phased Large Awards in Comparative Effectiveness Research (PLACER)**
 - PCORI encourages applicants to consider the potential merits of using PCORnet
 - LOIs due September 29, 2020
 - Expect LOI submissions from PCORnet Network Partners
- **Rare Disease PFA**
 - Open to all PCORnet Clinical Research Networks and Health Plan Research Networks and their partner organizations to perform an observational research study that will answer one or more important research questions about the care of patients with rare diseases
 - Applications submitted September 1, 2020 are under review by PCORI
- **Observational Analyses of Second-Line Pharmacological Agents in Type 2 Diabetes**
 - PCORI seeks to fund studies using observational designs that compare the effectiveness of newer versus older second-line pharmacological agents in type 2 diabetes mellitus among individuals at moderate cardiovascular risk
 - Applications submitted September 1, 2020 are under review by PCORI

PCORnet COVID-19 Data Efforts

COVID-19 Common Data Model



- PCORnet networks have created a stand-alone subset of the PCORnet Common Data Model (CDM) that includes COVID-19 positive patients
- Allows for a **reduction in the lag time** of transforming new data into the CDM from months to only days
- PCORnet COVID-19 CDM is being used **to support CDC COVID-19 surveillance**
 - Network Partners in discussions with CDC to provide support for the continued maintenance and use of COVID-19 CDM for surveillance
- Networks Partners are participating in Reagan-Udall and Friends of Cancer Research's COVID-19 **Evidence Accelerator initiative**
- **FDA's Sentinel** has engaged with PCORnet to support its work to describe the course of illness among hospitalized patients and evaluate therapies being used under real-world conditions

PCORnet COVID-19 Updates

Research Efforts



- [HERO Research Program](#)
- **COVID-19 Enhancement Awards**
 - [Health System Demonstration Project](#) “Identifying and Predicting Patients with Preventable High Utilization”
 - [Health System Demonstration Project](#) “Variation in Case Management Programs and Their Effectiveness in Managing High-Risk Patients for Medicare ACOs”
 - Partnerships to Conduct Research in [PCORnet PaCR Project](#) “Comparing Ways for Patients and Clinics to Improve Blood Pressure Control”
- **COVID-19 Targeted PFA**
 - Comparing Patient-Reported [Impact of COVID-19 Shelter-in-Place Policies and Access to Containment and Mitigation Strategies](#), Overall and in Vulnerable Populations
 - Evaluating the [Comparative Effectiveness of Telemedicine in Primary Care](#): Learning from the COVID-19 Pandemic

PCORI Investment in PCORnet



- **PCORI invested in the development of PCORnet, to improve the nation's capacity to conduct patient-centered research, to enable us to learn from the healthcare experiences of millions of Americans, and to allow for large-scale research to be conducted with enhanced accuracy and efficiency**
- PCORnet networks were designed to have coverage of large, diverse patient populations from a variety of health care settings with the ability to capture complete longitudinal healthcare data on this population, including EHR data from both ambulatory and inpatient care in the delivery system, and claims information or other records representing care received outside the delivery system
- The PCORnet infrastructure connects patients, clinicians, researchers, health systems, and health plans to expedite research that can improve health care and patient outcomes
- **During the COVID pandemic our primary emphasis has been to optimize the PCORnet infrastructure to facilitate PCORI and other public sector funders efforts to answer important patient-centered questions**

Cumulative PCORnet Directed Research Project Funding

October 1, 2013 – September 1, 2020 (\$131.3M)



- PCORI as awarded \$131M to supported research studies utilizing the PCORnet infrastructure
- This includes demonstration projects (14) and other funding initiatives that support several types of research:
 - Large, pragmatic clinical trial (ADAPTABLE)
 - Large observational studies (e.g., Bariatric Study)
 - HERO Research Program
 - Health system quality improvement/implementation science studies
 - Rapid Cycle Research and Projects Initiative
- PCORnet Network Partners are actively participating in other PCORI funded research studies utilizing the PCORnet infrastructure

Cumulative PCORnet Infrastructure Funding


October 1, 2013 – September 1, 2020 (\$357.4M)



- PCORI has invested \$357M in infrastructure funding for PCORnet over the last 7 years
- These funds have supported development and maintenance of several PCORnet infrastructure initiatives including:
 - Networks Partners (CRNs, PPRNs, HPRNs)
 - Coordinating Center
 - People-centered Research Foundation (PCRF)
 - Other infrastructure projects (e.g., data linkage)

PCORnet Infrastructure Yearly Expenses

- Total Coordinating Center, Clinical Research Network (CRN), and Health Plan Research Network (HPRN) expenses by year
- Infrastructure expenses were highest from FY15 to FY18 corresponding to a period of active network expansion and capacity building



*Projected FY20 Expenses

FY21 Placeholder Estimated Expenses

PCORnet Evaluation to Inform Board Discussions and Solicitations for Phase 3 Funding Currently Underway




Internal Evaluation

- PCORI staff is critically monitoring and assessing site-level CRN and HPRN performance:
 - Data quality and linkage performance
 - Population diversity and diversity of care settings
 - Network management participation
 - Participation in national, multi-network research projects, including contracting, IRB approval and recruitment metrics
- Staff is working with CC to strengthen measures of SES and racial diversity of patient populations
- This assessment will provide useful metrics to clarify site performance and help future funding decisions to “right size” the network.
- Process will inform Merit Review

External Evaluation

- PCORI has engaged RAND to provide a big picture evaluation of the Coordinating Center (CC)
 - How well is the PCORnet CC functioning with respect to its expected functions?
 - How does structure, funding and performance compare with other CC for similar networks?
- How might the structure, funding, governance or operations of the CC be changed to better meet PCORI’s goals?
- Should some operations be decentralized and build capabilities at network sites?
 - Should functions be split into separate units?

PCORnet Network Coverage




PCORnet COVID-19 Common Data Model


Demographics

As of July 14, 2020

Hospitalized COVID-19 positive patients age ≤ 19 (N= 674; 8 CRN pediatric hospital sites)




Ethnicity




Race

Hospitalized COVID-19 positive patients age ≥ 20 (N= 20,096; 34 CRN sites)



Ethnicity



Race

* Data are self-identified; Categories were defined by data collection

Anticipated PCORnet Phase 3 Timelines



PCORnet Coordinating Center and Networks	
Fall 2020	Board developing Phase 3 strategic vision
Jan 2021	Board consideration and vote
Early Winter 2021	Funding solicitations released
Late Summer 2021	Selection process, Board approval, Contracts finalized

- The extension funding will maintain the PCORnet networks and the Coordinating Center while Board develops its strategic vision for Phase 3, solicitations are developed, and awards are reviewed and selected.

Request to Commit FY2020 Budgeted Funds to Extend PCORnet Infrastructure Projects



- September 18, 2019, the Board approved PCORI's proposed budget for the 2020 fiscal year including \$37 million for PCORnet funding
 - Due to COVID-19 delays, Phase 3 solicitations originally planned for spring 2020 were not issued. Overall expenses have been less than anticipated
 - The proposed evaluation phase can be covered with existing budgeted funds
- We are requesting approval to **commit \$17 million of FY2020 budgeted funds** to extend the PCORnet networks and Coordinating Center infrastructure projects
- **No new unbudgeted funds** are requested for the extension
- The extension funding will maintain the PCORnet networks and the Coordinating Center while Board develops its strategic vision for Phase 3, solicitations are developed, and awards are reviewed and selected.

FY2020 Funding Commitment Plan



Award Commitments	Amount	Awarded in FY2020	Available for PCORnet Extension Period
Infrastructure	\$28.2 M	\$ 6.3 M	\$21.9 M
PCORnet Coordinating Center	\$14.0 M	\$6.1 M	7.9 M
Network Expansion – Health Plans and Additional CRNs	\$10.8 M		\$10.8 M
Natural Experiments Network – CDC	\$2.0 M		\$2.0 M
Supplemental Funding, other discretionary	\$1.4 M	\$0.2 M	\$1.2 M
PCORnet Research	\$9.0 M		\$9.0 M
Rapid Cycle Research	\$2.0 M		\$2.0 M
Partnerships to Conduct Research within PCORnet (PaCR) – Cycle II	\$6.0 M		\$6.0 M
Supplemental Funding, other discretionary	\$1.0 M		\$1.0 M
Total FY2020 Funding Commitment Plan	\$37.2 M		
Total Available for PCORnet Extension Period			\$30.9 M

Estimated Distribution of Extension Funding



Award Commitments	Amount
FY2020 Available Funds for PCORnet Extension Period	\$30,900,000
Funding for Extension Period • \$12,600,000 CRNs • \$ 100,000 HPRNs • \$ 3,300,000 CC	\$17,000,000
Total Available to Carry Forward to FY2021	\$13,900,000

Board Vote

Call for a Motion to:

- **Approve** up to \$17 million in funding to extend infrastructure projects of PCORnet networks and the PCORnet Coordinating Center

Call for the Motion to be Seconded:

- **Second** the Motion
- If further discussion, may propose an **Amendment** to the Motion or an **Alternative** Motion

Roll Call Vote:

- Vote to **Approve** the **Final** Motion
- Ask for votes in favor, opposed, and abstentions

Commitment Planning

Nakela L. Cook, MD, MPH

Executive Director



Purpose of Today's Discussion


Purpose: To determine the Commitment Planning Model for 2021-2030

- Considering opportunities and implications, what model is preferred?
 - What advantages and disadvantages do you see for your preferred option?
- What additional thoughts do you have about resources needed to accomplish the goals of the preferred option?
- How would you measure success; what metrics and targets resonate?

Options for the 2021-2030 Commitment Plan Model




All figures in Millions (\$)
D&I and Research lines represent *subsets* of the overall commitments (black line)




- All Commitments
- Research Commitments (subset)
- D&I Commitments (subset)


Steady State Model




Ramp Up/Down Model



Hybrid Model #1




Hybrid Model #2



2021-2030 Commitment Plan Options: Considerations

Model	Operations & Expenses	Flexibility for Large Commitments	Cash Flow Implications	Time Available for Results to Achieve Impact by 2029
Steady State	Stable staffing and operating model through FY3030	Greatest year-to-year and out-year flexibility of all models	Not committing ahead of revenue	~\$1.6B in new research will have results available for 5+ years
Ramp Up Ramp Down	Steep gear-up (~30%) then gear-down staffing and operating model	Least flexibility in out years	Committing ahead of revenue (>\$300M ahead of revenue in several years)	~\$2.0B in new research will have results available for 5+ years
Hybrid #1 (\$650M peak)	Significant gear-up (~20% increase) then gear-down staffing and operating model	Less flexibility in out years	Committing ahead of revenue (>\$100M ahead of revenue in several years)	~\$1.9B in new research will have results available for 5+ years
Hybrid #2 (\$550M peak)	Less effect on year-to-year staffing (~10% increase) and operating model than Hybrid #1	More year-to-year and out-year flexibility than other front-loaded models	Minimal committing ahead of revenue (~\$20M ahead in one year)	~\$1.8B in new research will have results available for 5+ years

Example: Context and Detail for Hybrid Model #2



Example: Projected 3-Year Commitment Plan for Hybrid Model #2 FY2021-2023



Funding Line (4 Larger Categories)	Projections for FY2020-2023 Average across FY2021-23: \$520-\$570M			
	FY2020 (\$M)	FY2021 (\$M)	FY2022 (\$M)	FY2023 (\$M)
Research	244	340	445	446
- Includes: - Half investigator-initiated, half PCORI-initiated via targeted, special emphasis, and priority topics - PLACER - Full range of research spectrum - Short-term and long-term priorities				
Dissemination & Implementation	31	40	55	55
- Includes: - Several lines of D&I Awards - Full range from Translation Center to large scale implementation projects - Other D&I Activities				
Infrastructure/Accelerating PCOR	38	102	43	37
- Includes: - Engagement Awards - Community Building - Workforce Awards - PCORnet Infrastructure Awards				
New Initiatives		50	50	50
New initiatives for research, D&I, and infrastructure				
Total Commitments	313	482 <i>(Up to 532)</i>	543 <i>(Up to 593)</i>	538 <i>(Up to 588)</i>

- Full complement of PFAs in all 3 cycles
- 50% increase in research commitments
- More than doubling of D&I commitments
- Infrastructure maintenance costs for PCORnet substantially less than building cost
- Average of \$50M per year available for new initiatives

Ramping Up Post Reauthorization

- Re-staffing key functions and expanding operations (e.g., program, merit review, and contracts)
- Reexamining processes for efficiencies
- Increased engagement with patients, stakeholders, and researchers
- Staffing and operational implications of different models:
 - Steady State Model: Very little change
 - Ramp Up/Ramp Down Model: ~30% rapid increase and drop
 - Hybrid #1 (\$650M peak): ~20% rapid increase
 - Hybrid #2 (\$550M peak): ~10% rapid increase

Defining Success: Potential Metrics and Targets


- Offering the full complement of PFAs in all 3 cycles
 - Broad PFAs, including areas of Special Emphasis
 - PCS/PLACER, including Priority Topics
 - Targeted, 1-2 per cycle
 - Novel PFA mechanisms
- Increased influx of applications and/or higher rate of fundable applications
 - Metrics/targets based on existing data
- Innovations/efficiencies in funding processes (without compromising quality)
 - Metrics/targets based on existing data

In addition to dollars committed

Options for 2021-2030 Commitment Plan Model

All figures in Millions (\$)


D&I and Research lines represent *subsets* of the overall commitments (black line)



— All Commitments
— Research Commitments (subset)
— D&I Commitments (subset)


Steady State Model

- Plan for steady state
- Maintain flexibility for large investments
- No committing ahead of revenue




Ramp Up/Down Model

- Steep peak and decline for research
- Reduced flexibility in later years
- Requires committing ahead of revenue




Hybrid Model #1

- ~\$550 early peak for research
- Somewhat reduced flexibility in later years
- Requires committing ahead of revenue



Hybrid Model #2

- ~\$450 early peak for research
- Maintains flexibility in later years
- Minimal committing ahead of revenue



Proposed Motions Corresponding to Options for Development of a Proposed 3-Year Commitment Plan



Call for a Motion to:

- Approve the development of a proposed 3-year Commitment Plan consistent with [SELECT]:
 - The proposed Steady State Approach Model
 - The proposed Ramp Up/Ramp Down Model
 - The proposed Hybrid #1 Model with a Peak of Approximately \$650
 - The proposed Hybrid #2 Model with a Peak of Approximately \$550
 - [Other model—characterize the key elements]

Discussion Questions

Commitment Planning Model 2021-2030

- Considering opportunities and implications, what model is preferred?
 - What advantages and disadvantages do you see for your preferred option?
- What additional thoughts do you have about resources needed to accomplish the goals of the preferred option?
- How would you measure success; what metrics and targets resonate?

Board Vote

Call for a Motion to:

- **Approve** the motion to develop a proposed 3-year Commitment Plan consistent with [Selected Model]

Call for the Motion to be Seconded:

- **Second** the Motion
- If further discussion, may propose an **Amendment** to the Motion or an **Alternative** Motion

Voice Vote:

- Vote to **Approve** the **Final** Motion
- Ask for votes in favor, opposed, and abstentions

Proposed FY2021 PCORI Budget

(October 1, 2020 – September 30, 2021)

Larry Becker

Chair, Finance & Administration Committee

Nakela L. Cook, MD, MPH

Executive Director

Key Definitions

Commitments and Expenses



COMMITMENTS

- **Award Commitments:** the amount of funding PCORI intends to award or has awarded, mostly in the form of multi-year contracts for Research, Research Infrastructure, Engagement, and Dissemination awards.
 - Note: Award commitments occur earlier than award payments. Expenses associated with award payments lag award commitments as research studies and other projects progress over time and are spread over multiple years.

Key Definitions

Commitments and Expenses



EXPENSES

- **Award Payments:** the amount PCORI pays to Research, Research Infrastructure, Engagement, and Dissemination awardees in response to invoices received for costs incurred under awarded contracts. These are direct costs associated with PCORI's funding award commitment plan.
 - Note: Award payments lag award commitments and the associated payments are spread over multiple years.
- **Program Services:** all program award payments, as well as all other direct program operating costs, including personnel, associated with the Science, Infrastructure, Engagement, and Dissemination departments, as well as the Methodology Committee.
- **Program Support Services:** all operational costs, including personnel, associated with the Evaluation & Analysis, Program Support & Information Management, and Communications departments.
- **Administrative Support:** all operational costs, including personnel, associated with general institutional infrastructure support (such as the Board and Management & General expenses).

Projected FY2020 Fund Balance



PROJECTED FUND BALANCE *		
Accrual Basis (\$ in millions)		
Fund Balance at September 30, 2019	\$	1,287
Revenue (FY2020)		455
Expenses (FY2020)		(364)
Fund Balance at September 30, 2020	\$	1,378
Outstanding Award Obligations at September 30, 2020	\$	(975)
Net Funds Available at September 30, 2020 **	\$	403

* Includes PCOR Trust Fund and bank accounts.

** These funds are available for new award commitments and operating costs.

Projected FY2021 Fund Balance



PROJECTED FUND BALANCE *	
Accrual Basis (\$ in millions)	
Fund Balance at September 30, 2020	\$ 1,378
Revenue (FY2021)	525
Expenses (FY2021)	(399)
Fund Balance at September 30, 2021	\$ 1,504
Outstanding Award Obligations at September 30, 2021 **	\$ (1,281)
Net Funds Available at September 30, 2021 ***	\$ 223

* Includes PCOR Trust Fund and bank accounts.

** Outstanding award obligations include assumptions about the planned commitment amounts in FY2021 and are subject to change.


*** These funds are available for new award commitments and operating costs.

Proposed FY2021 Budget

By Major Component

\$ in millions

Proposed FY2021 Budget



80% Award Payments

8% Other Direct Program Costs

5% Program Support Services

7% Administrative Support

	FY2021 Proposed Budget		FY2020 Projection		FY2020 Approved Budget	
REVENUE	\$	524.8	\$	454.9	\$	20.7
EXPENSES						
PROGRAM SERVICES						
Award Payments *	317.7	80%	297.1	82%	312.4	79%
Other Direct Program Costs	33.3	8%	28.7	8%	31.2	8%
TOTAL PROGRAM SERVICES	351.0	88%	325.8	90%	343.6	87%
PROGRAM SUPPORT SERVICES	19.2	5%	15.0	4%	17.3	4%
ADMINISTRATIVE SUPPORT	29.1	7%	22.9	6%	35.4	9%
TOTAL EXPENSES	\$	399.3	\$	363.7	\$	396.3

* Award payments are estimated expenses and are based predominantly on fully executed contracts for award commitments approved in prior years. PCORI management uses historical billing data to predict award payment amounts by research and other awardees over the period of a project which spans over multiple years.

Board Vote

Call for a Motion to:

- **Approve** the proposed FY2021 Budget

Call for the Motion to be Seconded:

- **Second** the Motion
- If further discussion, may propose an **Amendment** to the Motion or an **Alternative** Motion

Roll Call Vote:

- Vote to **Approve** the **Final** Motion
- Ask for votes in favor, opposed, and abstentions

BREAK

We will return at 2:45 PM ET



Join the conversation on Twitter via
@PCORI

Welcome Back

Christine Goertz, DC, PhD

Chairperson, Board of Governors



Strategic Planning Committee

Report to the Board

Sharon Levine, MD

Co-chair, Strategic Planning Committee

Nakela L. Cook, MD, MPH


Co-chair, Strategic Planning Committee




Draft Purpose Statement

- The Strategic Planning Committee will work on behalf of the PCORI Board of Governors, over the next 18 months, to develop and oversee the conduct of a strategic planning process and the development of a strategic plan for approval by the Board of Governors.
- Timeframe: Summer of 2020 to Fall of 2021


Original Strategic Framework (2013)



Potential Revised Strategic Framework




Strategic Planning: Components and Timeline




Overview of Strategic Planning Process

General Sequence




National Priorities

What Happens When



Input on National Priorities Received To Date

In June and July 2020, PCORI garnered input from several Advisory Panels and initial Board discussions. The input highlighted several points.



Additional Inputs for Strategic Planning Process

- Health care landscape review, noting potential shifts and implications for National Priorities
- Public input on National Priorities at PCORI's 2020 Annual Meeting
- Ongoing portfolio analyses
- Panel Discussions
 - Health Policymakers
 - Thought-Leaders
 - Congressional Leaders
- Other sources for input?

Thoughts and Feedback?

Panel Discussion with Outgoing Board Members

Reflections on 10 years of Board Service and Vision for the Future

Celebrating Their Service

Outgoing Board Members 2010-2020



Lawrence Becker

Current Chair of the Engagement, Dissemination, and Implementation Committee & Chair of the Finance and Administration Committee



Gail Hunt

Current Vice Chair of the Selection Committee



Freda Lewis-Hall, MD

Current Vice Chair of the Research Transformation Committee



Grayson Norquist, MD, MSPH

Former Board Chairperson

Panel Discussion with Outgoing Board Members

Reflections on 10 years of Board Service and Vision for the Future

Public Comment Period

Kristin Carman, MA, PhD

Director, Public & Patient Engagement

Closing Remarks

Wrap Up and Adjournment

 202.827.7700

 info@pcori.org

 www.pcori.org

 @pcori

 /PCORInstitute

 PCORI

 /pcori